文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

重症流感的抗病毒治疗:随机对照试验的系统评价与网络荟萃分析

Antivirals for treatment of severe influenza: a systematic review and network meta-analysis of randomised controlled trials.
PubMed 文献 · Lancet · 2024-01-01
一句话结论住院重症流感患者中,奥司他韦和帕拉米韦可能缩短住院时间(证据确定性低),对死亡率等结局影响很不确定。

为支持世界卫生组织(WHO)流感临床指南更新,本系统评价与网络荟萃分析检索了截至2023年9月20日的随机对照试验,纳入8项试验共1424例住院疑似或实验室确诊流感患者,其中6项进入网络荟萃分析。与安慰剂或标准治疗相比,奥司他韦缩短季节性流感住院时间平均差-1.63天(95%CI -2.81至-0.45),帕拉米韦-1.73天(-3.33至-0.13),均为低确定性证据。奥司他韦、帕拉米韦或扎那米韦对死亡率的影响为极低确定性证据;不良事件与严重不良事件无差异(极低确定性证据)。作者认为奥司他韦和帕拉米韦可能缩短住院时间,但证据确定性低,所有抗病毒药对死亡率和其他重要结局的影响很不确定。

要点

  • 住院重症流感患者中,与安慰剂或标准治疗相比,奥司他韦缩短季节性流感住院时间平均差-1.63天(95%CI -2.81至-0.45),证据确定性低。
  • 帕拉米韦同样缩短住院时间平均差-1.73天(95%CI -3.33至-0.13),证据确定性低。
  • 与标准治疗相比,奥司他韦(0.34天,95%CI -0.86至1.54)和帕拉米韦(-0.05天,95%CI -0.69至0.59)对症状缓解时间几乎无差别,证据确定性低。
  • 奥司他韦、帕拉米韦或扎那米韦对死亡率的影响为极低确定性证据;不良事件与严重不良事件无差异(极低确定性证据)。
  • 由于符合条件的试验数量少,无法检验发表偏倚;抗病毒药对其他结局的影响仍不确定。

适用人群与场景

  • 住院的疑似或实验室确诊流感患者(纳入标准),来自8项随机对照试验共1424例参与者;试验报告的平均或中位年龄为36-60岁,男性患者占43-78%。

研究设计与关键结果

  • 研究类型:系统评价与网络荟萃分析,纳入8项随机对照试验共1424例住院疑似或实验室确诊流感患者,其中6项试验进入网络荟萃分析。
  • 与安慰剂或标准治疗相比,奥司他韦缩短季节性流感住院时间平均差-1.63天(95%CI -2.81至-0.45),帕拉米韦-1.73天(95%CI -3.33至-0.13),均为低确定性证据。
  • 与标准治疗相比,奥司他韦对症状缓解时间平均差0.34天(95%CI -0.86至1.54),帕拉米韦-0.05天(95%CI -0.69至0.59),几乎无差别,均为低确定性证据。
  • 奥司他韦、帕拉米韦或扎那米韦对死亡率的影响(与安慰剂或未加安慰剂的标准治疗相比,针对季节性和人畜共患流感)为极低确定性证据。
  • 奥司他韦、帕拉米韦和扎那米韦的不良事件或严重不良事件无差异(极低确定性证据)。
  • 由于符合条件的试验数量少,无法检验发表偏倚。

证据类型、等级与局限

  • 证据类型:随机对照试验的系统评价与网络荟萃分析,采用GRADE方法评估证据确定性;研究注册号PROSPERO CRD42023456650。
  • 证据确定性:住院时间缩短为低确定性证据;症状缓解时间无差别为低确定性证据;死亡率影响为极低确定性证据;不良事件无差异为极低确定性证据。
  • 局限:由于符合条件的试验数量少,无法检验发表偏倚;抗病毒药对死亡率和其他重要患者结局的影响因随机对照试验数据稀缺而很不确定。

对床旁实践的改变

  • 作者认为,在住院重症流感患者中,与标准治疗或安慰剂相比,奥司他韦和帕拉米韦可能缩短住院时间,尽管证据确定性低。
  • 作者指出,所有抗病毒药对死亡率和其他重要患者结局的影响因随机对照试验数据稀缺而很不确定。

指南或共识出处

  • 世界卫生组织(WHO)流感临床指南(更新版,由本系统评价支持)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The optimal antiviral drug for treatment of severe influenza remains unclear. To support updated WHO influenza clinical guidelines, this systematic review and network meta-analysis evaluated antivirals for treatment of patients with severe influenza.

METHODS: We systematically searched MEDLINE, Embase, Cochrane Central Register of Controlled Trials, Cumulative Index to Nursing and Allied Health Literature, Global Health, Epistemonikos, and ClinicalTrials.gov for randomised controlled trials published up to Sept 20, 2023, that enrolled hospitalised patients with suspected or laboratory-confirmed influenza and compared direct-acting influenza antivirals against placebo, standard care, or another antiviral. Pairs of coauthors independently extracted data on study characteristics, patient characteristics, antiviral characteristics, and outcomes, with discrepancies resolved by discussion or by a third coauthor. Key outcomes of interest were time to alleviation of symptoms, duration of hospitalisation, admission to intensive care unit, progression to invasive mechanical ventilation, duration of mechanical ventilation, mortality, hospital discharge destination, emergence of antiviral resistance, adverse events, adverse events related to treatments, and serious adverse events. We conducted frequentist network meta-analyses to summarise the evidence and evaluated the certainty of evidence using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach. This study is registered with PROSPERO, CRD42023456650.

FINDINGS: Of 11 878 records identified by our search, eight trials with 1424 participants (mean age 36-60 years for trials that reported mean or median age; 43-78% male patients) were included in this systematic review, of which six were included in the network meta-analysis. The effects of oseltamivir, peramivir, or zanamivir on mortality compared with placebo or standard care without placebo for seasonal and zoonotic influenza were of very low certainty. Compared with placebo or standard care, we found low certainty evidence that duration of hospitalisation for seasonal influenza was reduced with oseltamivir (mean difference -1·63 days, 95% CI -2·81 to -0·45) and peramivir (-1·73 days, -3·33 to -0·13). Compared with standard care, there was little or no difference in time to alleviation of symptoms with oseltamivir (0·34 days, -0·86 to 1·54; low certainty evidence) or peramivir (-0·05 days, -0·69 to 0·59; low certainty evidence). There were no differences in adverse events or serious adverse events with oseltamivir, peramivir, and zanamivir (very low certainty evidence). Uncertainty remains about the effects of antivirals on other outcomes for patients with severe influenza. Due to the small number of eligible trials, we could not test for publication bias.

INTERPRETATION: In hospitalised patients with severe influenza, oseltamivir and peramivir might reduce duration of hospitalisation compared with standard care or placebo, although the certainty of evidence is low. The effects of all antivirals on mortality and other important patient outcomes are very uncertain due to scarce data from randomised controlled trials.

FUNDING: World Health Organization.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Gao Y, Guyatt G, Uyeki TM, et al. Antivirals for treatment of severe influenza: a systematic review and network meta-analysis of randomised controlled trials. Lancet. 2024. PMID: 39181595. doi:10.1016/S0140-6736(24)01307-2

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。